





DESCRIPTION	
<b>Species Reactivity</b>	Human
<b>Specificity</b>	Detects human Serpin E1/PAI-1 in direct ELISAs and Western blots. In direct ELISAs, approximately 15% cross-reactivity with recombinant mouse Serpin E1 is observed.
<b>Source</b>	Polyclonal Goat IgG
<b>Purification</b>	Antigen Affinity-purified
<b>Immunogen</b>	<i>S. frugiperda</i> insect ovarian cell line Sf21-derived recombinant human Serpin E1/PAI-1 Gly21-Pro402 Accession # P05121
<b>Formulation</b>	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

APPLICATIONS		
<b>Please Note:</b> Optimal dilutions should be determined by each laboratory for each application. <a href="#">General Protocols</a> are available in the Technical Information section on our website.		
	Recommended Concentration	Sample
<b>Western Blot</b>	1 µg/mL	See Below
<b>Immunohistochemistry</b>	5-15 µg/mL	See Below
<b>Immunoprecipitation</b>	25 µg/mL	Conditioned cell culture medium spiked with Recombinant Human Serpin E1/PAI-1 (Catalog # 1786-PI), see our <a href="#">available Western blot detection antibodies</a>
<b>Simple Western</b>	2.5 µg/mL	See Below
<b>Neutralization</b>	Measured by its ability to neutralize Recombinant Human Serpin E1 (1.35 µg/mL, Catalog # 1786-PI) inhibition of Recombinant Human u-Plasminogen Activator (uPA)/Urokinase (0.1 µg/mL, Catalog # 1310-SE) cleavage of the fluorogenic peptide substrate Z-GGR-AMC (100 µM). The Neutralization Dose (ND <sub>50</sub> ) is typically 10 µg/mL.	

## DATA



## PREPARATION AND STORAGE

<b>Reconstitution</b>	Reconstitute at 0.2 mg/mL in sterile PBS.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
<b>Stability &amp; Storage</b>	<p><b>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</b></p> <ul style="list-style-type: none"> <li>• 12 months from date of receipt, -20 to -70 °C as supplied.</li> <li>• 1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> <li>• 6 months, -20 to -70 °C under sterile conditions after reconstitution.</li> </ul>

## BACKGROUND

As a member of the Serpin superfamily of serine protease inhibitors, Serpin E1/PAI-1 is the principal inhibitor of urokinase-type plasminogen activator (uPA) and tissue-type PA (1, 2). As important regulators of extracellular matrix remodeling, uPA and PAI-1 play a major role in many processes such as angiogenesis, tumor invasion and obesity (2-4). For example, uPA and PAI-1 are the only tumor prognostic factors validated at the highest level of evidence with regard to their clinical utility in breast cancer (5). The human PAI-1 is initially synthesized as 402 amino acid precursor with a N-terminal signal peptide (6, 7). PAI-1 may exist in one of two possible conformations, designated as active or latent (8). The purified recombinant human (rh) PAI-1 is active against rhuPA. The heterogeneity at the N-terminus of the purified rhPAI-1 has been observed before for both the recombinant and native proteins (9).

### References:

1. Silverman, G.A. *et al.* (2001) *J. Biol. Chem.* **276**:33293.
2. Stefansson, S. *et al.* (2003) *Curr. Pharm. Des.* **9**:1545.
3. Duffy, M.J. (2002) *Clin. Chem.* **48**:1194.
4. Juhan-Vague, I. *et al.* (2003) *J. Thromb. Haemost.* **1**:1575.
5. Harbeck, N. *et al.* (2002) *Clin. Breast Cancer* **3**:196.
6. Pannekoek, H. *et al.* (1986) *EMBO J.* **5**:2539.
7. Ginsburg, D. *et al.* (1986) *J. Clin. Invest.* **78**:1673.
8. Wang, Z. *et al.* (1996) *Biochemistry* **35**:16443.
9. Stromqvist, M. *et al.* (1994) *Protein Expr. Purif.* **5**:309.